Home » Posts tagged with » ABM Therapeutics
ABM Therapeutics begins phase 1 trial of BRAF inhibitor ABM-1310

ABM Therapeutics begins phase 1 trial of BRAF inhibitor ABM-1310

ABM Therapeutics said that the first cancer patient has been enrolled and dosed with its lead candidate ABM-1310, a BRAF inhibitor, in a phase 1 clinical trial in the US. According to the clinical-stage biopharma company, the BRAF inhibitor had shown superior properties in pre-clinical animal models. The brain-penetrant small molecule is expected to be […]